I found the field of Pharmacology & Pharmacy very interesting. Saw the article Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors published in 2019. Recommanded Product: 50-84-0, Reprint Addresses Bagal, SK (corresponding author), Pfizer Global R&D UK, Worldwide Med Chem, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England.. The CAS is 50-84-0. Through research, I have a further understanding and discovery of 2,4-Dichlorobenzoic acid
Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23.
Recommanded Product: 50-84-0. Bye, fridends, I hope you can learn more about C7H4Cl2O2, If you have any questions, you can browse other blog as well. See you lster.
Reference:
Chloride – Wikipedia,
,Chlorides – an overview | ScienceDirect Topics